Regenerx Biopharmaceuticals Inc financial data

Symbol
RGRX on OTC
Industry
Pharmaceutical Preparations
Location
15245 Shady Grove Road, Suite 470, Rockville, MD
State of incorporation
DE
Fiscal year end
December 31
Former names
ALPHA 1 BIOMEDICALS INC (to 5/11/2001), ALPHA 1 BIOMEDICALS INC /DE/ (to 2/7/1995)

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 50.7 % -83.5%
Debt-to-equity -114 % +33.7%
Return On Equity 51.2 % -35.9%
Return On Assets -358 % -224%
Operating Margin -1.78K % +0.72%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 144M shares 0%
Common Stock, Shares, Outstanding 144M shares 0%
Entity Public Float 16M USD 0%
Common Stock, Value, Issued 144K USD 0%
Weighted Average Number of Shares Outstanding, Basic 144M shares 0%
Weighted Average Number of Shares Outstanding, Diluted 144M shares 0%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 76.8K USD 0%
Research and Development Expense 0 USD -100%
General and Administrative Expense 1.44M USD -0.26%
Operating Income (Loss) -1.36M USD +0.72%
Nonoperating Income (Expense) -326K USD -20.9%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -1.69M USD -2.83%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -1.69M USD -2.83%
Earnings Per Share, Basic -0.01 USD/shares 0%
Earnings Per Share, Diluted -0.01 USD/shares 0%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 102K USD -89%
Assets, Current 123K USD -86.9%
Operating Lease, Right-of-Use Asset 57.8K USD +257%
Other Assets, Noncurrent 5.75K USD 0%
Assets 187K USD -80.6%
Accounts Payable, Current 38.7K USD +22.1%
Accrued Liabilities, Current 469K USD +68.6%
Contract with Customer, Liability, Current 76.8K USD 0%
Liabilities, Current 1.8M USD +347%
Contract with Customer, Liability, Noncurrent 1.85M USD -3.98%
Operating Lease, Liability, Noncurrent 17.7K USD
Liabilities 3.93M USD +11.5%
Retained Earnings (Accumulated Deficit) -113M USD -1.52%
Stockholders' Equity Attributable to Parent -3.74M USD -45.9%
Liabilities and Equity 187K USD -80.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -189K USD +38.2%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 144M shares 0%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -189K USD +38.2%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 102K USD -89%
Deferred Tax Assets, Valuation Allowance 18.2M USD +1.74%
Deferred Tax Assets, Gross 18.2M USD +1.74%
Operating Lease, Liability 63.7K USD +291%
Lessee, Operating Lease, Liability, to be Paid 73.1K USD +331%
Operating Lease, Liability, Current 46K USD +182%
Lessee, Operating Lease, Liability, to be Paid, Year Two 32.2K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 40.9K USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 9.45K USD +1281%
Deferred Tax Assets, Operating Loss Carryforwards 14.5M USD +1.65%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 1M shares 0%
Unrecognized Tax Benefits 0 USD
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 511K USD +20.5%
Interest Expense 326K USD +0.24%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%